MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Varex Imaging Corporation Operating Income 2011-2026 | VREX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Varex Imaging Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.8 M | 32.1 M | 77.1 M | 88.2 M | 74.1 M | -33.7 M | 45.7 M | 44.5 M | 83.7 M | 109 M | 128 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 128 M | -33.7 M | 56.4 M |
Quarterly Operating Income Varex Imaging Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.4 M | - | -80.7 M | 22.1 M | 11.2 M | - | 9.3 M | 7.7 M | 4.2 M | - | 24.2 M | 15.6 M | 13 M | - | 23 M | 26.6 M | 14 M | - | 25.7 M | 15.8 M | 4.6 M | -20.8 M | -26.8 M | 1.4 M | - | 29.5 M | 4.6 M | 14.5 M | 10.4 M | 38.1 M | 7.3 M | 10.4 M | 13.6 M | 57.1 M | 15.5 M | 13.6 M | 18.6 M | 76.1 M | 28.4 M | 18.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.1 M | -80.7 M | 13.6 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 13.17 | 0.46 % | $ 1.78 B |  USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.8 | 4.05 % | $ 387 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.6 | -0.43 % | $ 216 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.47 | 4.52 % | $ 130 M |  France |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.12 | 3.92 % | $ 1.29 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 56.7 | 1.0 % | $ 1.67 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 61.0 | 1.5 % | $ 3.33 B |  Britain |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.37 | 1.7 % | $ 322 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.61 | 0.36 % | $ 38 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.65 | 3.92 % | $ 367 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.4 | 12.97 % | $ 1.14 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.41 | 14.22 % | $ 6.68 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 91.34 | 1.29 % | $ 12.4 B | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 100.01 | -0.77 % | $ 3.4 B | USA |
 |
NanoVibronix
NAOV
|
-22.9 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.8 | 0.38 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 84.03 | -5.06 % | $ 2.92 B | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 294.73 | -6.47 % | $ 113 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 83.98 | 0.57 % | $ 49.1 B | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 19.41 | -0.61 % | $ 1.32 B | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.61 | 7.27 % | $ 67.1 M | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.35 | 5.47 % | $ 54.9 M | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.68 | 9.52 % | $ 544 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.9 | 4.16 % | $ 37.7 M | USA |